Infliximab for the treatment of adult-onset pityriasis rubra pilaris.
Liao
Wennie C
WC
Department of Dermatology, University of Cincinnati, Cincinnati, Ohio, USA.
Mutasim
Diya F
DF
D000367:Age Factors; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010916:Pityriasis Rubra Pilaris / Q000175:diagnosis* / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab